Wang Jing, Liu Yaxue, Zhang Aohan, Yu Wenxin, Lei Qian, Xiao Bo, Luo Zhaohui
Department of Neurology, Xiangya Hospital, Central South University, Changsha 410008, China.
Xiangya School of Medicine, Central South University, Changsha 410083, China.
Cancers (Basel). 2022 Dec 2;14(23):5977. doi: 10.3390/cancers14235977.
Glioma is the most common primary malignancy of the central nervous system (CNS), and 50% of patients present with glioblastoma (GBM), which is the most aggressive type. Currently, the most popular therapies are progressive chemotherapy and treatment with temozolomide (TMZ), but the median survival of glioma patients is still low as a result of the emergence of drug resistance, so we urgently need to find new therapies. A growing number of studies have shown that the diversity, bioactivity, and manipulability of microorganisms make microbial therapy a promising approach for cancer treatment. However, the many studies on the research progress of microorganisms and their derivatives in the development and treatment of glioma are scattered, and nobody has yet provided a comprehensive summary of them. Therefore, in this paper, we review the research progress of microorganisms and their derivatives in the development and treatment of glioma and conclude that it is possible to treat glioma by exogenous microbial therapies and targeting the gut-brain axis. In this article, we discuss the prospects and pressing issues relating to these therapies with the aim of providing new ideas for the treatment of glioma.
胶质瘤是中枢神经系统（CNS）最常见的原发性恶性肿瘤，50%的患者为胶质母细胞瘤（GBM），这是最具侵袭性的类型。目前，最常用的治疗方法是逐步化疗和使用替莫唑胺（TMZ）治疗，但由于耐药性的出现，胶质瘤患者的中位生存期仍然很低，因此我们迫切需要寻找新的治疗方法。越来越多的研究表明，微生物的多样性、生物活性和可操作性使微生物疗法成为一种有前景的癌症治疗方法。然而，关于微生物及其衍生物在胶质瘤的发生发展和治疗方面的研究进展的众多研究较为分散，尚未有人对其进行全面总结。因此，在本文中，我们综述了微生物及其衍生物在胶质瘤的发生发展和治疗方面的研究进展，并得出结论：通过外源性微生物疗法和靶向肠-脑轴治疗胶质瘤是有可能的。在本文中，我们讨论了这些疗法的前景和紧迫问题，旨在为胶质瘤的治疗提供新思路。
